Abstract:ConspectusClustered, regularly interspaced, short palindromic repeat (CRISPR)/associated protein 9 (CRISPR/Cas9) is emerging as a powerful genome-editing tool, enabling precise and targeted modifications of virtually any genomic sequence in living cells. These technologies have potential therapeutic applications for cancers, metabolic diseases, and genetic disorders. However, several major challenges hinder the full realization of their potential. Specifically, CRISPR-Cas9 gene editors, whether delivered as plasmid DNA, mRNA/sgRNA, or ribonucleoprotein (RNP), exhibit poor membrane permeability, restricting their access to the intracellular genome, where the editing occurs. Additionally, these editors lack tissue or organ specificity, raising concerns about off-target editing at the tissue level that causes unwanted genotoxicity. Though a range of delivery carriers has been developed to deliver Cas9 editors, their effectiveness is often limited by a number of barriers at both the extracellular and intracellular levels. Moreover, the prolonged activity of Cas9 increases the risk of off-target editing at the genomic level. Therefore, it is crucial to develop efficient delivery vectors, along with molecular switches to safely regulate Cas9 activity.In this Account, we summarize our recent achievements in developing different types of materials that can efficiently deliver the plasmid DNA encoding Cas9 protein and single-guide RNA (sgRNA), or Cas9 RNP into cells to highlight the design considerations of carriers for safe and efficient delivery in vitro and in vivo. After elucidating the chemical and physical factors that are responsible for encapsulating and delivering these biomacromolecules, we further elucidate how we design the biodegradable polymeric carriers using dynamic disulfide chemistry, emphasize their safe and efficient delivery features for genome-editing biomacromolecules, and also introduce the integration of the intracellular delivery of genome-editing biomacromolecules with microneedle-based transdermal delivery to promote therapeutic genome editing for inflammatory skin disorders. Finally, we review how we exploit optical, chemical, and genetic switches to control the Cas9 activity in conjunction with targeted delivery to address the spatiotemporal specificity of gene editing in vivo and demonstrate their precision therapy against cancer and colitis treatment as proof-of-concept examples. In the final part, we will summarize the progress we have made and propose the future directions that may impact the field based on our own research outcomes.

Engineered exosomes with a photoinducible protein delivery system enable CRISPR-Cas-based epigenome editing in Alzheimer's disease

All-in-one AAV-delivered epigenome-editing platform: proof-of-concept and therapeutic implications for neurodegenerative disorders

An Episomal CRISPR/Cas12a System for Mediating Efficient Gene Editing

Non-viral Delivery of CRISPR–Cas9 Complexes for Targeted Gene Editing Via a Polymer Delivery System

In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease

Engineering self-deliverable ribonucleoproteins for genome editing in the brain

An exosome-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing

Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing

Ultrasound-Assisted CRISPRi-Exosome for Epigenetic Modification of Α-Synuclein Gene in a Mouse Model of Parkinson's Disease.

Efficient in vivo neuronal genome editing in the mouse brain using nanocapsules containing CRISPR-Cas9 ribonucleoproteins

Traceable Nano‐Biohybrid Complexes by One‐Step Synthesis as CRISPR‐Chem Vectors for Neurodegenerative Diseases Synergistic Treatment

Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer’s disease alleviates amyloid-related pathologies in mice

An Engineered Exosome for Delivering Sgrna:Cas9 Ribonucleoprotein Complex and Genome Editing in Recipient Cells.

Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing

Long term rescue of Alzheimer's deficits in vivo by one-time gene-editing of App C-terminus

Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice.

Long term rescue of Alzheimer deficits in vivo by one-time gene-editing of App C-terminus.

Cyclization-enhanced poly( β -amino ester)s vectors for efficient CRISPR gene editing therapy

Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing

Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins